Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.49 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6871916 | 0.92 | DHFR (0.53) | DHFR | |
| SCHEMBL6869438 | 0.92 | DHFR (0.55) | DHFR | |
| SCHEMBL6867847 | 0.86 | DHFR (0.54) | DHFR | |
| SCHEMBL6873233 | 0.81 | SRC (0.46) | — | |
| SCHEMBL7045275 | 0.76 | C5AR1 (0.44) | — | |
| SCHEMBL6862803 | 0.76 | ERN1 (0.43) | — | |
| SCHEMBL6870404 | 0.75 | C5AR1 (0.44) | — | |
| SCHEMBL7564683 | 0.74 | DHFR (0.56) | DHFR | |
| SCHEMBL6557526 | 0.73 | DHFR (0.66) | DHFR | |
| SCHEMBL6557380 | 0.73 | NTRK1 (0.64) | DHFRNTRK1CSF1RNTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280796-B1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2004-03-24 | — | — | EP | disclosed |
| US-6703397-B2 | REACTING A NITRILE GROUP CONTAINING INDOLE DERIVEATIVE WITH GUANIDINE OR SALT; USEFUL AS PROHYLAXIS OR THERAPEUTICAL TREATMENT OF INFECTIOUS DISEASES | BASILEA PHARMACEUTICA AG (CH) | 2004-03-09 | — | — | US | disclosed |
| US-20030119857-A1 | Pyrimidinyl methyl indole derivatives with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-06-26 | — | — | US | disclosed |
| EP-1280796-A1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001083474-A1 | PYRIMIDINYL METHYL INDOLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119857-A1 | Pyrimidinyl methyl indole derivatives with antibacterial activity | IDO1, IDO2, AANAT | DHFR 132/4885NTRK1 3070/4885CSF1R 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.